Cargando…
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in different age groups. One thousand five hundred tw...
Autores principales: | Kalmanti, Lida, Saussele, Susanne, Lauseker, Michael, Proetel, Ulrike, Müller, Martin C., Hanfstein, Benjamin, Schreiber, Annette, Fabarius, Alice, Pfirrmann, Markus, Schnittger, Susanne, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Krause, Stefan W., Heim, Dominik, Nerl, Christoph, Hossfeld, Dieter K., Kolb, Hans-Jochem, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889634/ https://www.ncbi.nlm.nih.gov/pubmed/24162333 http://dx.doi.org/10.1007/s00277-013-1937-4 |
Ejemplares similares
-
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018) -
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022) -
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020) -
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020) -
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
por: Miranda, M B, et al.
Publicado: (2016)